Moderna trial recruiting faster than protocol anticipated

Moderna’s projection that the first Phase III data from its COVID-19 vaccine may come in November instead of at year-end appears to be the result of faster recruitment than the trial’s protocol had assumed. 

On Thursday, Moderna Inc. (NASDAQ:MRNA) took the unusual step of publishing its complete protocol for the COVE study, which is evaluating the vaccine vs. placebo in 30,000 volunteers. The move coincided with its R&D day...